Company Profile
Revolutionizing Radiopharmaceutical Development through the Innovative Peptide Discovery Platform CUS™
Founded in 2017, C-Biomex Co., Ltd is a pioneering bio-venture focused on advancing novel theranostics using its exclusive peptide discovery platform technology.
At present, C-Biomex distinguishes itself from traditional peptides through its notable attributes of heightened serum stability, remarkable binding affinity, and selectivity for specific target molecules. These advantages hold considerable promise across a spectrum of therapeutic applications, offering potential advantages in terms of both effectiveness and safety. Currently, we are focusing on peptide radiopharmaceuticals, a field that facilitates the targeted transport of radioactive isotopes to cancerous tissues for dual diagnostic and therapeutic purposes. Supported by robust preclinical data, we are making swift strides in advancing our research and development.
Vision & Mission
Growing Together
We will establish fair and sincere partnerships with both domestic and international research institutions and biotech companies. Additionally, we are committed to building trust with shareholders and investors, aiming for mutual growth.
Growing Together
We will establish fair and sincere partnerships with both domestic and international research institutions and biotech companies. Additionally, we are committed to building trust with shareholders and investors, aiming for mutual growth.
Growing Together
We will establish fair and sincere partnerships with both domestic and international research institutions and biotech companies. Additionally, we are committed to building trust with shareholders and investors, aiming for mutual growth.
Growing Together
We will establish fair and sincere partnerships with both domestic and international research institutions and biotech companies. Additionally, we are committed to building trust with shareholders and investors, aiming for mutual growth.
